UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED ~~DECEMBER~~MARCH 31, ~~2022~~2023

Commission File Number 000-56112

GENUFOOD ENERGY ENZYMES CORP.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

1108 S. Baldwin Avenue, Suite 107

Arcadia, California 91007

(Address of principal executive offices, including zip code.)

(855) 707-2077

(Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
N/A		N/A		N/A

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: ~~299~~808,~~686~~900,~~921~~ 041 shares as of ~~February~~March 1331, 2023.

GENUFOOD ENERGY ENZYMES CORP.

FORM 10-Q FOR THE ~~THREE~~SIX-MONTH PERIOD ENDED ~~DECEMBER~~MARCH 31, ~~2022~~2023

TABLE OF CONTENTS

		Page Number
	PART I. FINANCIAL INFORMATION

ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	1
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	13
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	18
ITEM 4.	CONTROLS AND PROCEDURES	18

	PART II. OTHER INFORMATION	20

ITEM 1.	LEGAL PROCEEDINGS	20
ITEM 1A.	RISK FACTORS	20
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	20
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	20
ITEM 4.	MINE SAFETY DISCLOSURES	20
ITEM 5.	OTHER INFORMATION	20
ITEM 6.	EXHIBITS	21

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

GENUFOOD ENERGY ENZYMES CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

	December 31,			September 30,
	March 31,			September 30,
	2022			2022
	2023			2022
ASSETS	(Unaudited)
	(Unaudited)			(Restated)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	46311,~~526~~133		$	136,400
Prepayment		69,~~657~~537			14,493
Total Current Assets		53320,~~183~~670			150,893
Equipment		1520,~~005~~167			-
Total Assets	$	68340,~~188~~837		$	150,893
LIABILITIES AND STOCKHOLDERS’ DEFICIT
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	~~118~~100,~~471~~115		$	102,185
Due to related parties		134,213			102,831
Accrued expenses		40			-
Total Current Liabilities		252,684			205,016
Due to related parties		4,776			102,831
Commitment and contingencies (Note 9)		29,976			29,226
Total Current Liabilities		104,931			205,016
STOCKHOLDERS’ DEFICIT
Commitment and contingencies (Note 9)		30,726			29,226
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 299,686,921 and 299,686,921 shares issued and outstanding as of December 31, 2022 and September 30, 2022 respectively		299,687			299,687
STOCKHOLDERS’ EQUITY (DEFICIT)
Additional paid-in capital		17,050,058			16,975,058
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 808,900,041 and 299,686,921 shares issued and outstanding as of March 31, 2023 and September 30, 2022, respectively		808,900			299,687
Additional paid-in capital		16,952,092			16,927,592
Discount on common stock		(7,241,581	)		(7,241,581	)
Accumulated other comprehensive loss		(193,643	)		(193,558	)
Accumulated deficit		(10,314,231	)		(9,875,489	)
Accumulated deficit		(10,128,993	)		(9,922,955	)
Accumulated other comprehensive loss		-			(193,558	)
Total Stockholders’ Deficit		(214,472	)		(83,349	)
Total Stockholders’ Equity (Deficit)		205,180			(83,349	)
Total Liabilities and Stockholders’ Deficit	$	68,188		$	150,893
Total Liabilities and Stockholders’ Equity	$	340,837		$	150,893

1The accompanying notes are an integral part of these condensed consolidated financial statements.

~~GENUFOOD ENERGY ENZYMES CORPORATION~~1

~~CONDENSED~~GENUFOOD ~~CONSOLIDATED~~ENERGY ~~STATEMENTS~~ENZYMES ~~OF OPERATIONS AND COMPREHENSIVE LOSS~~CORPORATION

~~(UNAUDITED)~~CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	For the Three Months Ended December 31,
	2022			2021
REVENUE	$	-		$	-
OPERATING EXPENSES
General and administrative expenses		205,245			103,340
Total operating expenses		205,245			103,340
LOSS FROM OPERATIONS		(205,245	)		(103,340	)
OTHER INCOME (EXPENSE)
Interest income (expense)		-			1
Foreign currency (loss) income		(43	)		2
Other non-operating income (expenses), net		(750	)		(750	)
Total other expense		(793	)		(747	)
Loss before income taxes		(206,038	)		(104,087	)
Income tax expense		-			-
NET LOSS	$	(206,038	)	$	(104,087	)
OTHER COMPREHENSIVE LOSS
Foreign currency transaction adjustment		(85	)		(8	)
COMPREHENSIVE LOSS	$	(206,123	)	$	(104,095	)
BASIC AND DILUTED LOSS PER SHARE	$	*		$	*
WEIGHTED AVERAGE NUMBER OF COMMON STOCKS-BASIC AND DILUTED		299,686,921			299,686,921

(UNAUDITED)

* Less than $0.01 per share

	For the Three Months Ended March 31,						For the Six Months Ended March 31,
	2023			2022			2023			2022
REVENUE	$	-		$	-		$	-		$	-

OPERATING EXPENSES
General and administrative expenses		95,839			62,085			244,834			165,425
Total operating expenses		95,839			62,085			244,834			165,425

LOSS FROM OPERATIONS		(95,839	)		(62,085	)		(244,834	)		(165,425	)

OTHER INCOME (EXPENSE)
Interest income (expense)		-			2			-			3
Loss on disposal of subsidiary		(192,365	)		-			(192,365	)		-
Foreign currency income (loss)		-			4			(43	)		6
Other non-operating income (expenses), net		(750	)		(1,145	)		(1,500	)		(1,895	)
Total other (expense) income		(193,115	)		(1,139	)		(193,908	)		(1,886	)

Loss before income taxes		(288,954	)		(63,224	)		(438,742	)		(167,311	)

Provision for income taxes		-			-			-			-

NET LOSS		(288,954	)		(63,224	)		(438,742	)		(167,311	)

OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency transaction adjustments		193,643			6			193,558			(2	)

COMPREHENSIVE LOSS	$	(95,311	)	$	(63,218	)	$	(245,184	)	$	(167,313	)

BASIC & DILUTED LOSS PER SHARE		*			*			*			*

WEIGHTED AVERAGE NUMBER OF ORGINARY SHARES-BASIC & DILUTED		473,950,309			299,686,921			385,390,227			299,686,921

2* Less than $0.01 per share

~~GENUFOOD~~The ~~ENERGY~~accompanying ~~ENZYMES~~notes ~~CORPORATION~~are an integral part of these condensed consolidated financial statements.

~~CONDENSED CONSOILDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY~~2

~~(UNAUDITED)~~GENUFOOD ENERGY ENZYMES CORPORATION

	Common Stock				Additional		Discount on						Accumulated Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Deficit
BALANCE AT SEPTEMBER 30, 2022		299,686,921	$	299,687	$	16,975,058	$	(7,241,581	)	$	(9,922,955	)	$	(193,558	)	$	(83,349	)
Stock-based compensation		-		-		75,000		-			-			-			75,000
Foreign currency translation		-		-		-		-			-			(85	)		(85	)
Net loss		-		-		-		-			(206,038	)		-			(206,038	)
BALANCE AT DECEMBER 31, 2022		299,686,921	$	299,687	$	17,050,058	$	(7,241,581	)	$	(10,128,993	)	$	(193,643	)	$	(214,472	)

CONDENSED CONSOILDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

	Common Stock				Additional		Discount on						Accumulated Other			Total
	Number of				Paid-in-		stock			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Capital		common			Deficit			Income (loss)			Equity
BALANCE AT SEPTEMBER 30, 2021		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,522,821	)	$	(193,583	)	$	253,472
Foreign currency translation		-		-		-		-			-			(8	)		(8	)
Net loss		-		-		-		-			(104,087	)		-			(104,087	)
BALANCE AT DECEMBER 31, 2021		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,626,908	)	$	(193,591	)	$	149,377

(UNAUDITED)

	Common Stock				Additional			Discount on						Accumulated Other			Total
	Number of				Paid-in-			common			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Capital			stock			Deficit			Income (loss)			Equity
Balance at September 30, 2022 (restated)		299,686,921	$	299,687	$	16,927,592		$	(7,241,581	)	$	(9,875,489	)	$	(193,558	)	$	(83,349	)
Foreign currency translation															(85	)		(85	)
Stock based compensation (restated)						18,750												18,750
Net loss (restated)												(149,788	)					(149,788	)
Balance at December 31, 2022 (restated)		299,686,921		299,687		16,946,342			(7,241,581	)		(10,025,277	)		(193,643	)		(214,472	)
Common stock issued		375,000,000		375,000		(13,000	)											362,000
Issuance of common stock for debt conversion		134,213,120		134,213														134,213
Stock-based compensation						18,750												18,750
Disposal of subsidiary															193,643			193,643
Net loss												(288,954	)					(288,954	)
Balance at March 31, 2023		808,900,041	$	808,900	$	16,952,092		$	(7,241,581	)	$	(10,314,231	)	$	-		$	205,180

GENUFOOD ENERGY ENZYMES CORPORATION

													Accumulated
	Common Stock				Additional		Discount on						Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Equity
Balance at September 30, 2021		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,522,821	)	$	(193,583	)	$	253,472
Foreign currency translation														(8	)		(8	)
Net loss											(104,087	)					(104,087	)
Balance at December 31, 2021		299,686,921		299,687		16,911,770		(7,241,581	)		(9,626,908	)		(193,591	)		149,377
Foreign currency translation														6			6
Net loss											(63,224	)					(63,224	)
Balance at March 31, 2022		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,690,132	)	$	(193,585	)	$	86,159

~~CONDENSED~~The ~~CONSOLIDATED~~accompanying ~~STATEMENTS~~notes OFare ~~CASH~~an ~~FLOWS~~integral part of these condensed consolidated financial statements.

~~(UNAUDITED)~~3

	For the Three Months Ended December 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(206,038	)	$	(104,087	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		75,000			-
Change in operating assets and liabilities:
Prepayment		7,836			7,406
Accounts payable		17,401			(3,337	)
Accrued expenses		-			(851	)
Due to related parties		30,182			28,581
Commitment and contingencies		750			750
Net cash used in operating activities		(74,869	)		(71,538	)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of Hukui investment		-			350,000
Purchase of equipment		(15,005	)		-
Net cash (used in) provided by financing activities		(15,005	)		350,000
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		-			-
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(89,874	)		278,462
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		136,400			9,271
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	46,526		$	287,733
SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

GENUFOOD ENERGY ENZYMES CORPORATION

4CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

~~GENUFOOD ENERGY ENZYMES CORP~~(UNAUDITED)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	For the Six Months Ended March 31,
	2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(438,742	)	$	(167,311	)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation		37,500			-
Loss on disposal of subsidiary		192,365			-
Change in operating assets and liabilities
Prepayment		4,956			4,887
Accounts payable		323			(3,307	)
Accrued expenses		40			(1,590	)
Due to related parties		34,958			49,515
Commitment and contingencies		1,500			1,500
Net cash used in operating activities		(167,100	)		(116,306	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment		(20,167	)		-
Proceeds from sale of Hukui investment		-			350,000
Net cash (used in) provided by financing activities		(20,167	)		350,000

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock		362,000			-
Net cash provided by financing activities		362,000			-

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		174,733			233,694

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		136,400			9,271

CASH AND CASH EQUIVALENTS - END OF PERIOD	$	311,133		$	242,965

SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock for debt conversion	$	134,213		$	-

~~(UNAUDITED)~~The accompanying notes are an integral part of these condensed consolidated financial statements.

~~NOTE 1 – GENERAL ORGANIZATION AND BUSINESS~~4

~~Genufood Energy~~GENUFOOD ~~Enzymes~~ENERGY ~~Corp.,~~ENZYMES USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which ceased its operations on January 9, 2023.CORP

~~Since~~NOTES ~~its inception,~~TO ~~the~~CONDENSED ~~Company~~CONSOLIDATED ~~has~~FINANCIAL always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the three months ended December 31, 2022, the Company has initiated its electric vehicle charging station business.STATEMENTS

~~The Company made two investments in Hukui Biotechnology Corporation~~ (~~“Hukui”~~UNAUDITED) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

OnNOTE ~~August~~ 1, ~~2022,~~– ~~the board~~GENERAL ~~of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle~~ORGANIZATION ~~supply~~AND equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.BUSINESS

OnGenufood Energy ~~October~~Enzymes 26Corp., ~~2022, the~~USA ~~Company entered into three Charging Station Site Host Agreements~~ (the “~~Agreements~~Company”) ~~with~~or ~~two institutions (the~~ “~~Site Hosts~~GEEC”), ~~respectively,~~was ~~pursuant~~incorporated tounder ~~which~~ the ~~Site~~laws ~~Hosts~~of ~~agree~~the toState ~~allow~~of ~~the~~Nevada ~~Company~~on June to21, ~~install~~2010. ~~its~~On ~~electric~~February ~~vehicle~~13, ~~charging~~2012, ~~stations at~~GEEC ~~the~~incorporated ~~locations~~a ~~set~~wholly-owned ~~forth~~subsidiary, inGenufood ~~the~~Enzymes ~~Agreements~~ (~~the~~S) ~~“Charging~~Pte ~~Stations~~Ltd (“GESPL”). ~~Under the Agreements~~in Singapore, ~~the~~which ~~Company~~ has ~~agreed~~been todissolved ~~share the~~on ~~revenue~~January ~~generated~~9, ~~by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein~~2023.

AsSince ~~of December 31~~its inception, ~~2022,~~ the Company has ~~purchased certain~~always ~~electric~~been ~~vehicle~~in ~~charging equipment. Furthermore,~~ the ~~Company~~development isstage inand ~~the~~never ~~process~~generated ofsignificant ~~obtaining~~revenues. ~~permits~~The toCompany ~~construct~~is ~~the~~currently ~~Charging~~developing ~~Stations~~business atin ~~the~~Electric ~~three~~Vehicle ~~confirmed~~Charge ~~sites~~station. AsThe ofCompany ~~December~~has ~~31,~~engaged ~~2022,~~in ~~the~~business ~~Company~~agreements ~~contracted~~and andevelopment ~~architectural~~with ~~firm~~various onparties. ~~providing~~During the ~~designing~~six ~~and engineering~~months ~~services~~ended ~~for~~March ~~two~~31, ~~sites~~2023, ~~and~~the ~~working~~Company onhas ~~technical~~initiated ~~issues~~its ~~for~~electric ~~the~~vehicle ~~third~~charging ~~site~~station business.

AsThe Company made two investments in Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of ~~February~~Hukui’s 13Series C Preferred Stock for $800,000 on ~~2023~~December 15, ~~the~~2020; ~~Company~~and ~~has~~purchasing 60,000 shares ~~received~~of Hukui’s Series C Preferred Stock ~~the~~for ~~finalized~~$600,000 on ~~site~~June ~~plans~~25, ~~and~~2021. ~~electrical~~The ~~diagrams~~Company, ~~from~~an individual and resident of the ~~architectural~~Republic ~~firm~~of China (the “Purchaser”), and Hukui, ~~electrical~~entered ~~engineers~~into ~~for~~a 2Stock ~~sites.~~Purchase ~~The~~Agreement dated as of November 17, 2021, pursuant to which the Company ~~has~~agreed ~~also~~to sell these 140,000 shares ~~received~~of ~~permission~~Hukui’s ~~from~~Series C Preferred Stock (the ~~site~~“Hukui ~~owners~~Shares”) to ~~proceed~~the ~~with~~Purchaser ~~the~~for ~~charging~~$350,000 in ~~station~~cash, ~~construction~~or ~~permit~~$2.50 per share. ~~applications~~The ~~with~~sale of the ~~local~~Hukui ~~municipalities~~Shares closed on November 19, 2021.

~~NOTE~~On August 1, 2022, the 2board –of ~~SUMMARY~~directors OF(the ~~SIGNIFICANT~~“Board”) ~~ACCOUNTING~~of ~~POLICIES~~the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

~~Basis~~On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of ~~Presentation~~electricity at the Charging Stations with the Site Hosts.

~~The~~As ~~Company’s condensed~~of ~~consolidated~~March ~~financial~~31, ~~statements~~2023, the ~~have~~Company ~~been~~has ~~prepared~~purchased incertain ~~accordance~~electric ~~with~~vehicle ~~generally~~charging ~~accepted accounting principles in the United States of America (“US GAAP”)~~equipment. ~~The accompanying condensed consolidated financial statements reflect all adjustments~~Furthermore, ~~consisting of~~the ~~only~~Company ~~normal~~is ~~recurring items, which,~~ in the ~~opinion~~process of ~~management,~~obtaining ~~are~~permits to ~~necessary~~construct ~~for a fair statement of~~ the ~~results~~Charging ofStations ~~operations~~at ~~for~~ the ~~periods~~three ~~shown~~confirmed ~~and~~sites. ~~are~~As ~~not necessarily indicative~~ of ~~the~~March ~~results~~31, to2023, ~~be expected for~~ the ~~full~~Company ~~year~~contracted ~~ending~~an ~~September~~architectural ~~30,~~firm ~~2023. These~~on ~~condensed~~providing ~~consolidated~~designing ~~financial~~and ~~statements~~engineering ~~should~~services befor ~~read~~two insites, ~~conjunction with the consolidated financial statements~~ and ~~related~~working ~~notes included in the Company’s Annual Report~~ on ~~Form~~technical ~~10-K~~issues for the ~~year~~third ~~ended September 30, 2022~~site.

~~Principle~~As of ~~Consolidation~~February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities.

The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities during the three months ended December 31, 2022 and 2021. 5

~~Use of~~NOTE ~~Estimates~~2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

~~The preparation~~Basis of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.Presentation

5The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022.

~~GENUFOOD~~Principle ~~ENERGY~~of ~~ENZYMES CORP NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~Consolidation

~~(UNAUDITED)~~The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities prior to its dissolution.

~~Concentrations of~~Use ~~Credit Risk~~of Estimates

~~Financial~~The preparation ~~instruments~~of ~~that~~the ~~potentially~~condensed ~~subject~~consolidated ~~the~~financial ~~Company~~statements toin ~~significant~~conformity ~~concentrations~~with ofUS ~~credit~~GAAP ~~risk~~requires ~~consisted~~management ~~primarily~~to ofmake ~~cash,~~estimates toand ~~the~~assumptions ~~extent~~that ~~balances~~affect ~~exceeded~~the ~~limits~~reported ~~that~~amounts ~~were~~of ~~insured~~assets byand ~~the~~liabilities ~~Federal~~and ~~Deposit~~disclosure ~~Insurance~~of ~~Corporation.~~contingent ~~The~~assets ~~Company~~and ~~does~~liabilities ~~not~~at ~~require~~the ~~collateral~~date ~~and~~of ~~maintains~~the consolidated ~~reserves~~financial ~~for~~statements ~~potential~~and ~~credit~~the ~~losses.~~reported ~~Such~~amounts ~~losses~~of ~~have~~revenues ~~historically~~and ~~been~~expenses ~~immaterial~~during ~~and~~the ~~have~~reporting ~~been~~period. ~~within~~Actual ~~management’s~~results ~~expectations~~could differ from those estimates.

~~Cash~~Concentrations ~~and~~of ~~Cash~~Credit ~~Equivalents~~Risk

~~The Company~~Financial ~~considers~~instruments ~~all~~that ~~highly~~potentially ~~liquid~~subject ~~instruments~~the ~~with~~Company ~~original~~to ~~maturities~~significant concentrations of ~~three~~credit ~~months~~risk orconsisted ~~less~~primarily ~~when~~of ~~acquired~~cash, to bethe ~~cash equivalents. As of December~~extent ~~31,~~balances ~~2022~~exceeded ~~and~~limits ~~September~~that ~~30,~~were ~~2022,~~insured by the ~~Company~~Federal ~~did~~Deposit ~~not~~Insurance ~~have cash equivalents~~Corporation. The Company’s ~~cash~~does ~~was~~not ~~denominated~~require incollateral ~~United~~and ~~States~~maintains ~~Dollars~~reserves ~~(“USD”)~~for orpotential ~~New~~credit ~~Taiwan~~losses. ~~Dollars~~Such ~~(“TWD”)~~losses ~~and~~have ~~was~~historically ~~placed~~been ~~with~~immaterial ~~banks~~and inhave ~~the~~been ~~United~~within ~~States~~management’s ~~of America and Taiwan~~expectations.

~~Fair~~Cash ~~Value~~and ofCash ~~Financial Instruments~~Equivalents

The Company ~~follows~~considers ~~the~~all ~~guidance~~highly liquid instruments with original maturities of ~~the~~three ~~ASC~~months ~~Topic~~or ~~820-10,~~less ~~“Fair~~when ~~Value~~acquired ~~Measurements~~to ~~and~~be ~~Disclosures”~~cash ~~(“ASC~~equivalents. ~~820-10”),~~As ~~with~~of ~~respect~~March to31, ~~financial~~2023 ~~assets~~ and ~~liabilities~~September ~~that~~30, ~~are~~2022, ~~measured~~the atCompany ~~fair~~did ~~value.~~not ~~ASC~~have ~~820-10~~cash ~~establishes~~equivalents. aThe ~~three-tier~~Company’s ~~fair~~cash ~~value~~was ~~hierarchy~~denominated ~~that~~in ~~prioritizes~~United States ~~the~~Dollars ~~inputs~~(“USD”) ~~used~~or New Taiwan Dollars (“TWD”) and was placed with banks in ~~measuring~~the ~~fair~~United ~~value~~States asof ~~follows:~~America and Taiwan.

● Level 1 inputs are quoted prices available for identical assets and liabilities in active markets. ● Level 2 inputs are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets and liabilities in active markets or other inputs that are observable or can be corroborated by observable market data. ● Level 3 inputs are less observable and reflect our own assumptions.6

~~The Company’s~~Fair ~~financial~~Value ~~instruments consist principally~~ of ~~cash~~Financial and cash equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.Instruments

~~Foreign~~The Company ~~Currency~~follows ~~Translation~~the guidance of the ASC Topic 820-10, “Fair Value Measurements and ~~Transactions~~Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

~~The~~● ~~reporting~~ Level 1 inputs are quoted prices available for identical assets and ~~functional~~liabilities ~~currency~~in ofactive ~~GEEC~~markets. is● Level 2 inputs are observable for the ~~USD.~~asset ~~The~~or ~~functional~~liability, ~~currency~~either ofdirectly ~~GESPL~~or indirectly, aincluding ~~wholly~~quoted ~~owned~~prices ~~subsidiary~~for ofsimilar ~~GEEC,~~assets isand ~~the~~liabilities ~~Singapore~~in ~~Dollar (“SGD”)~~active markets or other inputs that are observable or can be corroborated by observable market data. ● Level 3 inputs are less observable and reflect our own assumptions.

~~For~~The ~~financial reporting purposes, the financial statements of the~~ Company’s ~~Singapore subsidiary, which are prepared using the SGD, are translated~~ ~~into~~financial ~~the~~instruments ~~Company’s~~consist ~~reporting~~principally ~~currency,~~of ~~USD. Assets~~cash and ~~liabilities~~cash ~~are translated using the exchange rate on the balance sheet date~~equivalents, ~~which~~accounts ~~was~~payable ~~0.7464~~ and ~~0.6970~~accrued asexpenses ~~of December 31, 2022~~ and ~~September~~due ~~30,~~to ~~2022,~~related ~~respectively~~parties. ~~Revenue and expenses are translated using~~ ~~average exchange rates prevailing during each reporting period.~~ The ~~0.7214 and 0.7370 average~~ ~~exchange~~carrying ~~rates were~~amounts ~~used~~of tosuch ~~translate~~financial ~~revenues~~instruments ~~and~~in ~~expenses for~~ the ~~three~~accompanying ~~months~~consolidated ~~ended~~balance ~~December~~sheets ~~31,~~approximate ~~2022~~their ~~and~~fair ~~2021,~~values ~~respectively.~~due ~~Stockholders’~~to ~~equity~~their isrelatively ~~translated~~short-term atnature. ~~historical~~It ~~exchange~~is ~~rates.~~management’s ~~Adjustments~~opinion ~~resulting~~that ~~from~~ the ~~translation~~Company ~~are~~is ~~recorded~~not asexposed ato ~~separate~~any ~~component~~significant ~~of accumulated~~currency ~~other~~or ~~comprehensive~~credit risks ~~loss~~arising infrom ~~stockholders’~~these ~~deficit~~financial instruments.

~~Transactions~~Foreign ~~denominated~~Currency inTranslation ~~currencies~~and other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.Transactions

6The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

~~GENUFOOD~~For ~~ENERGY~~financial reporting ~~ENZYMES~~purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated ~~CORP~~into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet ~~NOTES~~date, TOwhich ~~CONDENSED~~was ~~CONSOLIDATED~~0.6970 ~~FINANCIAL~~as ~~STATEMENTS~~of September 30, 2022. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for the six months ended March 31, 2022. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

~~(UNAUDITED)~~Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included in the accompanying condensed consolidated statements of operations.

Business Segments

The Company operates in only one segment.

Net Income (Loss) Per Share

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is ~~computed~~ computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the ~~three~~six months ended March ~~December~~ 31, ~~2022~~ 2023 and ~~2021~~2022.

~~Discounts on Common Stock~~7

~~Common stock~~Discounts issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on ~~the~~Common ~~Company’s condensed consolidated financial statements.~~Stock

~~Stock-Based~~Common ~~Compensation~~stock issued lower than the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.

~~The Company accounts for its stock~~Stock-~~based~~Based ~~compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718,~~ Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

~~Income~~The Company ~~Taxes~~accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

Income ~~taxes~~ are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.Taxes

~~The~~Income ~~Company~~taxes ~~considers~~are ~~positive~~accounted ~~and~~for ~~negative~~under ~~evidence~~the ~~when~~asset ~~determining~~and ~~whether~~liability amethod. ~~portion~~Deferred ~~or all of its deferred~~ tax assets ~~will~~and ~~more~~liabilities ~~likely~~are ~~than~~recognized ~~not be~~for ~~realized.~~the ~~This~~future ~~assessment~~tax ~~considers,~~consequences attributable ~~among~~to ~~other~~differences ~~matters,~~between the ~~nature,~~financial ~~frequency~~statement ~~and~~carrying ~~severity~~amounts of ~~current~~existing assets and ~~cumulative~~liabilities ~~losses,~~and ~~forecasts of~~their ~~future~~respective ~~profitability, the duration of statutory carry-forward periods, its experience with~~ tax bases ~~attributes~~and ~~expiring~~operating ~~unused,~~loss and ~~its~~ tax ~~planning~~credit ~~strategies~~carry forwards. ~~The~~Deferred ~~ultimate realization of deferred~~ tax assets isand ~~dependent~~liabilities ~~upon~~are ~~its~~measured ~~ability~~using toenacted ~~generate~~tax ~~sufficient~~rates ~~future taxable~~expected ~~income~~to ~~within~~apply ~~the~~to ~~carry-forward~~taxable ~~periods~~income ~~provided for~~ in the ~~tax~~years ~~law~~in ~~and~~which ~~during~~those ~~the~~temporary ~~periods~~differences inare ~~which~~expected ~~the~~to ~~temporary~~be ~~differences~~recovered ~~become~~or ~~deductible~~settled. ~~When~~ ~~assessing~~The ~~the~~effect ~~realization~~on of deferred tax assets, ~~the~~and ~~Company~~liabilities ~~has considered possible sources~~ of ~~taxable~~a ~~income~~change ~~including~~in ~~(i)~~tax ~~future reversals~~rates ofis ~~existing~~recognized ~~taxable~~in ~~temporary~~income ~~differences,~~in ~~(ii)~~the ~~future~~period ~~taxable~~that ~~income~~includes ~~exclusive~~the ofenactment ~~reversing~~date. ~~temporary~~A ~~differences and carry-forwards,~~valuation ~~(iii)~~allowance ~~future~~is ~~taxable~~recorded ~~income~~to ~~arising~~reduce ~~from~~the ~~implementing~~Company’s deferred tax ~~planning~~assets ~~strategies,~~to ~~and~~the ~~(iv)~~amount ~~specific~~that ~~known~~is ~~trend~~more oflikely ~~profits~~than ~~expected~~not to be ~~reflected~~ ~~within the industry~~realized.

7The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

~~GENUFOOD~~The ~~ENERGY~~Company recognizes ~~ENZYMES~~a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position ~~CORP~~will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, ~~NOTES~~the TOCompany ~~CONDENSED~~initially ~~CONSOLIDATED~~and ~~FINANCIAL~~subsequently ~~STATEMENTS~~measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

~~(UNAUDITED)~~There were no current and deferred income tax provision recorded for the six months ended March 31, 2023 and 2022 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.8

~~There were~~Recent noAccounting current and deferred income tax provision recorded for the three months ended December 31, 2022 and 2021 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.Pronouncements

~~Recent~~The Company considers the applicability and impact of all Accounting ~~Pronouncements~~Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

~~The~~In ~~Company~~August ~~considers~~2020, the ~~applicability~~FASB ~~and~~issued ~~impact~~Accounting ofStandards ~~all~~Update ~~Accounting~~No. ~~Standards~~2020-06, ~~Updates~~Debt ~~(“ASUs”~~– orDebt ~~“ASU”~~with Conversion and Other Options (Subtopic 470-20) onand Derivatives ~~the~~and ~~Company~~Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments ~~consolidated~~and Contracts in an Entity’s Own Equity. This ASU addresses complex financial ~~statements~~instruments that have characteristics of both debt and equity. ~~Updates~~The ~~not~~application ~~listed~~of ~~below~~this ~~were~~ASU ~~assessed~~would reduce the number of accounting models for convertible debt instruments and ~~determined~~convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be ~~either~~subject ~~not~~to ~~applicable~~separation ormodels are ~~expected~~(1) tothose with ~~have~~embedded ~~minimal~~conversion ~~impact~~features onthat are not clearly and closely related to the ~~Company’s~~host ~~consolidated~~contract, ~~financial~~that ~~position~~meet orthe ~~results~~definition of ~~operations.~~a ~~Recently~~derivative, and ~~issued~~that ~~ASUs~~do ~~that~~not ~~the~~qualify ~~Company feels~~for ~~may~~a bescope ~~applicable~~exception tofrom derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the ~~Company~~premiums are recorded as ~~follows:~~paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

~~In August~~NOTE ~~2020,~~3 ~~the FASB issued Accounting Standards Update No. 2020-06, Debt~~ – ~~Debt~~GOING with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.CONCERN

~~NOTE~~As of March 331, –2023 ~~GOING~~and ~~CONCERN~~September 30, 2022, the Company had an accumulated deficit of $10,314,231 and $9,875,489, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of its common stock and investment. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

AsThe ~~of December~~Company ~~31,~~sold ~~2022 and September 30~~the 140,000 Hukui ~~2022,~~Shares ~~the~~for ~~Company had an accumulated deficit of~~ $10350,~~128,993~~000 ~~and~~in ~~$9,922,955,~~cash ~~respectively.~~on ToNovember ~~date~~19, ~~the Company’s~~2021. ~~cash~~The ~~flow~~proceeds ~~requirements~~ have been ~~primarily~~used ~~met~~for ~~through~~operation ~~proceeds received from sales of Common Stock and investment~~expenses. ~~These~~ ~~and~~Management ~~other~~is ~~factors~~currently ~~raise~~seeking ~~substantial~~additional ~~doubt~~funds ~~about~~for ~~the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible~~ future ~~effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern~~operation.

~~The~~NOTE ~~Company~~4 ~~sold~~– the 140,000 Hukui Shares for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking additional funds for the Company’s future operation.EQUIPMENT

8As of March 31, 2023, and September 30, 2022 the Company had equipment of $20,167 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations.

~~GENUFOOD ENERGY ENZYMES~~NOTE ~~CORP NOTES~~5 TO– ~~CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~INVESTMENT

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (~~UNAUDITED~~the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment was recorded at cost.

~~NOTE~~On 4November 17, –2021, ~~EQUIPMENT~~the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000, The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.

AsNOTE of6 ~~December~~– ~~31,~~STOCKHOLDERS’ ~~2022~~EQUITY ~~and September 30, 2022, the Company had equipment of $15,005 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations.~~(DEFICIT)

~~NOTE~~The Company 5is –authorized ~~INVESTMENT~~under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

Pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock ~~at $10.00 per share, for a total purchase price of~~ $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment is recorded at cost.Options

On ~~November~~July 1715, ~~2021~~2022, the ~~Company~~CEO, ~~entered~~David ~~into~~Tang, awas ~~stock purchase agreement to sell all~~granted ~~140~~15,000,000 ~~Hukui~~options ~~Shares~~to purchase shares at $20.5001 per share. ~~for~~As aof March 31, 2023, total ofoptions ~~$350~~granted was 15,000,000 and none was vested. ~~The~~This ~~sale~~option ~~was~~will ~~completed~~be onsubject ~~November~~to ~~19,~~a ~~2021,~~vesting ~~resulting~~schedule inproviding ~~loss~~for oftwenty-five percent ~~$1,050,000.~~(25%) ~~The~~vesting ~~Company~~after ~~recognized~~the ~~impairment~~first ~~loss~~ twelve (12) months of employment and monthly vesting as to the ~~market~~remaining ~~value~~seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of ~~$1,050,000~~the employment commencement date. These stock options are exercisable over a maximum period of ~~for~~10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, ~~2021~~2022 was $0.02.

~~NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)~~9

~~The~~Compensation costs associated with the Company is’s ~~authorized~~stock ~~under~~options ~~its~~are ~~articles~~recognized, based on the grant-date fair value of ~~incorporation~~these options, asover ~~amended~~the requisite service period, toor ~~issue~~vesting period. Accordingly, 10the Company recognized stock-based compensation expense of $37,~~000~~500 and $0,~~000~~ respectively,~~000 shares~~ which was included in the general and administrative expenses in the condensed consolidated statements of ~~Common~~operations for ~~Stock~~the six months ended March 31, ~~par~~2023 ~~value~~and $02022.~~001 per share.~~

~~Stock~~The fair ~~Options~~value of the stock options listed above was determined using the Black-Scholes option pricing model with the following assumptions:

On July 15, 2022, the CEO, David Tang, was granted 15,000,000 options to purchase shares at $0.01 per share. As of December 31, 2022, total options granted was 15,000,000 and none was vested. This option will be subject to a vesting schedule providing for twenty-five percent (25%) vesting after the first twelve (12) months of employment and monthly vesting as to the remaining seventy-five percent (75%) of the shares over the following thirty-six (36) months after the first anniversary of the employment commencement date. These stock options are exercisable over a maximum period of 10 years from the grant date. The weighted average grant date fair value of options granted during the year ended September 30, 2022 was $0.02.

	March 31, 2023
Risk-free interest rate		2.99	%
Expected term		6.08 years
Expected volatility		379.35	%
Expected dividend yield		0	%

~~Compensation costs~~The ~~associated with the Company’s stock options are recognized, based on the grant-date fair value of these options, over the~~following ~~requisite~~is ~~service~~a ~~period,~~summary ~~or vesting period. Accordingly, the Company recognized stock-based compensation expense~~ of ~~$75,000 and $0, respectively, which was included in~~ the ~~general~~option ~~and~~activity ~~administrative expenses in the condensed consolidated statements of operations~~ for the ~~three~~six months ended ~~December~~March 31, ~~2022 and 2021.~~2023:

Options	Number of Underlying Shares		Weighted average exercise price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at October 1, 2022		15,000,000	$	0.01		–	$	–
Granted		–	$	–		–	$	–
Exercised		–	$	–		–	$	–
Forfeited or expired		–	$	–		–	$	–
Outstanding at March 31, 2023		15,000,000	$	0.01		9.3	$	225,000
Vested and expected to vest as of March 31, 2023		15,000,000	$	0.01		9.3	$	225,000
Exercisable at March 31, 2023		–	$	–		–	$	–

~~GENUFOOD~~As ~~ENERGY~~of ~~ENZYMES~~March ~~CORP~~31, 2023, unrecognized total compensation cost associated with these options was $246,678. This expense is expected to be ~~NOTES~~recognized TOover ~~CONDENSED~~a ~~CONSOLIDATED~~weighted-average ~~FINANCIAL~~period ~~STATEMENTS~~of 3.29 years.

~~(UNAUDITED)~~10

~~The fair~~NOTE ~~value~~7 of– ~~the~~RELATED ~~stock~~PARTY ~~options listed above was determined using the Black-Scholes option pricing model with the following assumptions:~~ TRANSACTIONS

	September 30, 2022			September 30, 2021
Risk-free interest rate		2.99	%		–
Expected term		6.08 years			–
Expected volatility		379.35	%		–
Expected dividend yield		0	%		–

Related Parties

~~The~~Name ~~following is~~of arelated ~~summary~~parties ofRelationship with the ~~option~~Company ~~activity~~Yi ~~for~~Lung ~~the~~(Oliver) ~~three~~Lin ~~months~~Principal ~~ended~~shareholder ~~December~~Jui 31Pin (John) Lin Principal shareholder, ~~2022:~~Director, Former President and Chief Executive Officer Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-Piao (Jack) Lai Director, Former President and Chief Executive Officer Shao-Cheng (Will) Wang Chief Financial Officer Kuang Ming (James) Tsai Director Nan-Yao (Jake) Chan Former Director Hsin-Ta (Darren) Su Director, Treasurer Hui-Chuan (Sandra) Lin Director and Secretary, daughter of Jui Pin (John) Lin

Options	Number of Underlying Shares		Weighted average exercise price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at October 1, 2022		15,000,000	$	0.01		–	$	–
Granted		–	$	–		–	$	–
Exercised		–	$	–		–	$	–
Forfeited or expired		–	$	–		–	$	–
Outstanding at December 31, 2022		15,000,000	$	0.01		9.5	$	330,000
Vested and expected to vest as of December 31, 2022		15,000,000	$	0.01		9.5	$	330,000
Exercisable at December 31, 2022		–	$	–		–	$	–

Due to Related Parties

AsThe ~~of December~~Company’s ~~31,~~due ~~2022, unrecognized total compensation cost associated with these options was $161,712. This expense is expected~~ to ~~be recognized~~related ~~over~~parties abalances ~~weighted-average~~are ~~period~~as ~~of 3.54 years.~~follows:

NOTE 7 – RELATED PARTY TRANSACTIONS

	March 31, 2023		September 30, 2022
Kuang Ming (James) Tsai	$	-	$	20,755
Jui Pin (John) Lin		-		8,048
Jia Tian (Jeffery) Lin		-		2,500
Shao-Cheng (Will) Wang		-		27,600
Wen-Piao (Jack) Lai		-		22,210
Hsin-Ta (Darren) Su		550		17,189
Hui-Chuan (Sandra) Lin		-		4,529
David Tang		4,226		-
Total	$	4,776	$	102,831

~~Related~~The ~~Parties~~related party balances are unsecured, interest-free and due on demand.

~~Name~~NOTE of8 ~~related~~– ~~parties~~INCOME Relationship with the Company Yi Lung (Oliver) Lin Principal shareholder Jui Pin (John) Lin Principal shareholder, Director, Former President and Chief Executive Officer Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-Piao (Jack) Lai Director, Former President and Chief Executive Officer Shao-Cheng (Will) Wang Chief Financial Officer Kuang Ming (James) Tsai Director Nan-Yao (Jake) Chan Former Director Hsin-Ta (Darren) Su Director, Treasurer Hui-Chuan (Sandra) Lin Director and Secretary, daughter of Jui Pin (John) LinTAXES

10The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively. The Singapore subsidiary has been inactive since 2016 and dissolved in January 2023.

~~GENUFOOD ENERGY ENZYMES CORP NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~11

Internal Revenue Code (~~UNAUDITED~~“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

~~Due~~The Company believes that based on the current information available, it is difficult to ~~Related~~determine ~~Parties~~whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.

~~The~~During the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company’s for failure to file Form 5472, Information ~~due~~Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020. The Company has engaged an outside professional advisor to ~~related~~seek ~~parties~~for ~~balances~~forgiveness ~~are~~of the penalty and interest thereon in the amount of $5,726, for a total of $30,726, which was still pending as ~~follows:~~of March 31, 2023.

	December 31, 2022		September 30, 2022
Kuang Ming (James) Tsai	$	26,155	$	20,755
Jui Pin (John) Lin		17,048		8,048
Jia Tian (Jeffery) Lin		2,500		2,500
Shao-Cheng (Will) Wang		34,500		27,600
Wen-Piao (Jack) Lai		24,010		22,210
Hsin-Ta (Darren) Su		18,271		17,189
Hui-Chuan (Sandra) Lin		9,929		4,529
Nao-Yao (Jake) Chan		1,800		-
Total	$	134,213	$	102,831

NOTE 9 – COMMITMENTS AND CONTINGENCIES

The ~~related~~Company ~~party~~terminated ~~balances~~its ~~are~~previous ~~unsecured~~virtual office agreement in Los Angeles, ~~interest-free~~California and ~~due~~has established a new virtual office in Arcadia, California. The new arrangement is on ~~demand~~a month-to-month basis at a cost of $200 per month. As of March 31, 2023, the Company has no material commitments under operating leases.

~~NOTE~~During 8the fiscal –year ~~INCOME~~ended ~~TAXES~~September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 8).

~~The Company~~NOTE ~~has~~10 ~~not~~– ~~generated~~SUBSEQUENT any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively, and the Singapore subsidiary has been inactive since 2016.EVENTS

~~Internal~~Management ~~Revenue~~has ~~Code~~evaluated ~~(“IRC”)~~subsequent ~~Section~~events ~~6038(a)~~pursuant ~~requires information reporting with respect~~ to ~~certain foreign corporations (Form 5471) and describes~~ the ~~information~~requirements ~~required~~of toASC beTopic ~~reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10~~855,~~000 for each~~ ~~Form~~from ~~5471~~the ~~that~~balance issheet ~~filed~~date ~~after~~through the ~~due~~ date ofwhen the ~~income~~consolidated financial ~~tax~~statements ~~return~~were ~~(including~~issued ~~extensions) or does not include the complete~~ and ~~accurate information~~determined ~~described~~that inno ~~Section~~subsequent ~~6038(a).~~events ~~According~~occurred tothat ~~IRS~~would ~~rules,~~require aadjustment ~~penalty may apply~~ to ~~each~~or ~~Form~~disclosure ~~5471~~in ~~which is filed after~~ the ~~due date~~ ofconsolidated ~~the~~financial ~~income tax return~~statements. ~~The penalty will be applied whether or not any tax is due on Form 1120.~~

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed.12

~~During~~ITEM ~~the fiscal year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return of a 25% Foreign-Owned U~~2.S. ~~Corporation or a Foreign Corporation Engaged in a U.~~MANAGEMENT’S. ~~Trade~~DISCUSSION orAND ~~Business,~~ANALYSIS ~~for~~OF ~~the~~FINANCIAL ~~year~~CONDITION ~~ended~~AND ~~September 30,~~RESULTS ~~2020.~~OF The Company has engaged an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $4,976, for a total of $29,976, which was still pending as of December 31, 2022OPERATIONS.

11CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

~~GENUFOOD~~This ~~ENERGY~~document ~~ENZYMES~~contains “forward-looking ~~CORP~~statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of ~~NOTES~~1933 TOand ~~CONDENSED~~Section 21E ~~CONSOLIDATED~~of ~~FINANCIAL~~the ~~STATEMENTS~~Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

~~(UNAUDITED)~~Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect”, “anticipate”, “hope” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

~~NOTE~~Although we believe that the 9expectations –reflected ~~COMMITMENTS~~in ~~AND~~any ~~CONTINGENCIES~~of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:

~~The~~● ~~Company terminated~~risks ~~its~~related ~~previous~~to ~~virtual~~our ~~office~~ability ~~agreement~~to ~~in Los Angeles~~identify, ~~California~~pursue and ~~has~~commence ~~established~~ a ~~new~~reverse ~~virtual~~merger ~~office~~and/or ~~in Arcadia, California. The new arrangement is on~~ a ~~month-to-month~~possible ~~basis at a cost of $200 per month. As of December 31, 2022, the Company had no material commitments under~~ operating ~~leases.~~business;

~~During~~● ~~the fiscal~~our ~~year~~ability ~~ended~~to ~~September~~obtain ~~30,~~adequate ~~2021,~~funding ~~the IRS imposed a $25,000 penalty on the Company for failure~~ to ~~file~~complete ~~Form 5472, Information Return of~~ a ~~25%~~ ~~Foreign-Owned~~reverse ~~U.S.~~merger ~~Corporation~~ or acommence ~~Foreign Corporation Engaged in~~ a ~~U.S.~~possible ~~Trade~~operating orbusiness ~~Business,~~and ~~for~~meet ~~the~~our ~~year~~operating ~~ended~~expenses ~~September 30,~~on ~~2020~~a ~~(see~~current ~~Note 8).~~basis;

~~NOTE 10~~● –general ~~SUBSEQUENT~~economic ~~EVENTS~~uncertainty, whether as a result of the COVID-19 pandemic or otherwise;

~~The~~● ~~Company has~~delays ~~closed~~in ~~GESPL,~~our ~~its~~ability ~~Singapore~~to ~~subsidiary~~obtain any necessary business licenses and permits, asand ofcommence ~~January~~business 9operations, ~~2023.~~whether ~~GESPL~~as ~~does~~a ~~not~~result ~~have~~of ~~any~~the ~~operation.~~COVID-19 pandemic or otherwise; and

~~Management has~~● ~~evaluated~~current ~~subsequent~~and ~~events~~longer-term ~~pursuant~~economic toand ~~the~~other ~~requirements~~impacts of ~~ASC~~the ~~Topic~~COVID-19 ~~855~~pandemic on our operations, ~~from~~results ~~the~~of ~~balance~~operations ~~sheet~~and ~~date~~financial ~~through~~condition, ~~the~~including ~~date~~without ~~when~~limitation ~~the~~changes ~~consolidated financial~~in ~~statements~~consumer ~~were~~spending ~~issued~~patterns ~~and~~for ~~determined~~non-essential ~~that~~products, noresulting ~~subsequent~~from ~~events~~the ~~occurred~~economic ~~that~~crisis ~~would~~caused ~~require~~by ~~adjustment~~lockdown, toshelter-in-place, stay-at-home or ~~disclosure~~similar inorders instituted as a result of the ~~consolidated~~ ~~financial~~pandemic, ~~statements~~or otherwise.

12Overview

~~ITEM 2~~On August 1, 2022, the board of directors (the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, ~~MANAGEMENT’~~2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. ~~DISCUSSION~~The ~~AND~~Company ~~ANALYSIS~~intends OFto bring ~~FINANCIAL~~convenient, ~~CONDITION~~reliable, ~~AND~~and ~~RESULTS~~accessible OFcharging ~~OPERATIONS~~experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

~~CAUTIONARY~~On October 26, 2022, we entered ~~STATEMENT~~into ~~REGARDING~~three ~~FORWARD-LOOKING~~Charging ~~STATEMENTS~~Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, we have agreed to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.13

~~Forward-looking statements~~As ~~may~~of ~~include~~December ~~the words “may~~31,” ~~“could~~2022,” ~~“will,” “estimate,” “intend,”~~the ~~“continue,”~~Company ~~“believe,”~~has ~~“expect”,~~purchased ~~“anticipate”,~~certain ~~“hope”~~electric orvehicle ~~other~~charging ~~similar words~~equipment. ~~These~~ ~~forward-looking~~Furthermore, ~~statements~~the ~~present~~Company ~~our~~is ~~estimates~~in ~~and~~the ~~assumptions~~process ~~only~~of asobtaining ofpermits to construct the ~~date~~Charging ofStations ~~this~~at ~~report~~the three confirmed sites. ~~Except~~As ~~for~~of ~~our~~December ~~ongoing~~31, ~~obligation to~~2022, ~~disclose~~the ~~material~~Company ~~information~~contracted asan ~~required~~architectural byfirm ~~the~~on providing ~~federal~~designing ~~securities~~and ~~laws,~~engineering weservices dofor ~~not~~two ~~intend~~sites, and ~~undertake~~working noon ~~obligation,~~technical toissues ~~update any~~for ~~forward-looking~~the ~~statement~~third site.

~~Although~~As of February 13, 2023, the weCompany ~~believe~~has ~~that~~received the ~~expectations~~finalized ~~reflected~~site inplans ~~any~~and ofelectrical ~~our~~diagrams ~~forward-looking~~from ~~statements~~the ~~are~~architectural ~~reasonable,~~firm ~~actual~~and ~~results~~electrical ~~could~~engineers ~~differ~~for ~~materially~~2 sites. ~~from~~The ~~those~~Company ~~projected~~has oralso ~~assumed~~received inpermission ~~any~~from ofthe ~~our~~site ~~forward-looking~~owners ~~statements.~~to ~~Our~~proceed ~~future~~with ~~financial~~the ~~condition~~charging ~~and~~station ~~results~~construction ofpermit ~~operations,~~applications aswith ~~well~~the aslocal ~~any~~municipalities. ~~forward-looking~~The ~~statements,~~Company ~~are~~expects ~~subject~~ to ~~change~~install ~~and~~up ~~inherent~~to ~~risks~~a ~~and~~total ~~uncertainties. Some~~ of ~~the~~10 ~~key~~charging ~~factors~~units ~~impacting these~~for ~~risks~~the ~~and~~first ~~uncertainties~~2 ~~include~~sites, ~~but~~and ~~are~~have ~~not~~them ~~limited~~operational in ~~to:~~April of 2023.

●Hukui ~~risks related to our ability to identify, pursue and commence a reverse merger and/or a possible operating business;~~Investment

●Hukui ~~our~~Biotechnology ~~ability~~Corporation (“Hukui”) and we entered into a Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to ~~obtain~~which ~~adequate~~we ~~funding~~agreed to ~~complete~~purchase aan ~~reverse~~aggregate ~~merger~~200,000 orshares ~~commence~~of aHukui’s ~~possible~~Series ~~operating~~C ~~business~~Preferred ~~and~~Stock ~~meet~~(the “Series ~~our~~C ~~operating~~Preferred ~~expenses~~Shares”) onat a$10.00 ~~current~~per ~~basis;~~share, for an aggregate investment of $2,000,000.

●The ~~general~~Hukui ~~economic~~Agreement ~~uncertainty,~~provided that ~~whether~~we aswould apurchase ~~result~~the ofSeries ~~the~~C ~~COVID-19~~Preferred ~~pandemic~~Shares in three tranches, through a date on or ~~otherwise;~~before June 30, 2022, as follows:

● ~~delays~~The infirst ~~our~~tranche ~~ability~~is to80,000 ~~obtain~~Series ~~any~~C ~~necessary~~Preferred ~~business~~Shares ~~licenses~~in ~~and~~the ~~permits~~amount of $800,000 ~~and~~(the ~~commence~~“First ~~business~~Tranche ~~operations~~Investment”), ~~whether~~such asshares ahaving ~~result~~been ofpurchased ~~the~~by ~~COVID-19~~us ~~pandemic~~on orDecember ~~otherwise;~~15, ~~and~~2020 (the “First Tranche Closing”);

● ~~current~~The ~~and~~second ~~longer-term~~tranche ~~economic~~is ~~and other impacts of the COVID-19 pandemic on our operations~~60,000 ~~results~~Series ofC ~~operations~~Preferred ~~and~~Shares ~~financial condition, including without limitation changes~~ in ~~consumer~~the ~~spending~~amount ~~patterns~~of ~~for non-essential products~~$600,000 ~~resulting from~~ (the ~~economic~~“Second ~~crisis~~Tranche ~~caused by lockdown~~Investment”), ~~shelter-in-place,~~such ~~stay-at-home~~shares orhaving ~~similar~~been ~~orders~~purchased ~~instituted~~by asus aon ~~result~~June of25, 2021 (the ~~pandemic,~~“Second orTranche ~~otherwise.~~Closing”); and

~~Overview~~● The third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Third Tranche Investment”), such shares to have been purchased on or before June 30, 2022 (the “Third Tranche Closing”).

OnAn ~~August~~individual 1,and ~~2022,~~resident of the ~~board~~Republic of ~~directors~~China (the “~~Board~~Purchaser”) of, ~~the~~Hukui ~~Company~~and ~~unanimously~~we ~~approved~~entered tointo ~~expand~~a ~~our~~Stock ~~business~~Purchase inAgreement ~~the~~dated ~~area~~as of ~~electric~~November ~~vehicle~~17, 2021 ~~supply equipment~~ (the “~~EVSE~~Stock Purchase Agreement”), ~~and~~pursuant ~~will direct~~to ~~the~~which ~~management~~we ~~team~~agreed to ~~implement~~sell ~~its~~the ~~new business plan in such industry. On August 16~~140,000 ~~2022,~~shares ~~the~~of ~~Company~~Hukui’s ~~formally~~Series ~~announced~~C ~~its~~Preferred ~~intention~~Stock tothat ~~reposition~~we ashad ~~EVSE~~purchased ~~solutions provider, seeking to grow business~~ in ~~EVSE~~the ~~industry,~~First ~~including~~Tranche ~~building,~~Closing ~~owning,~~ and ~~operating~~ the ~~next~~Second ~~generation~~Tranche ofClosing ~~electric~~(the ~~vehicle~~“Hukui ~~charging~~Shares”) ~~stations~~to in the ~~U.S.~~Purchaser for ~~The~~$350,000 ~~Company~~in ~~intends to bring convenient~~cash, ~~reliable,~~or ~~and~~$2.50 ~~accessible charging~~per ~~experience~~share. toThe ~~electric~~sale ~~vehicle~~of ~~drivers,~~the ~~utilizing~~Hukui ~~frictionless~~Shares ~~technology~~closed ~~and~~on ~~carbon-neutral~~November ~~vehicle-charging~~19, ~~infrastructure~~2021.

On ~~October~~ 26December 17, ~~2022~~2021, Hukui and we entered into ~~three~~an ~~Charging~~Agreement ~~Station Site Host Agreements~~ (the “~~Agreements”)~~Termination ~~with two institutions (the “Site Hosts~~Agreement”), ~~respectively,~~ pursuant to which ~~the~~our ~~Site~~obligation ~~Hosts agree~~ to ~~allow~~make usthe toThird ~~install our electric vehicle charging~~Tranche ~~stations~~Investment atwas ~~the~~terminated ~~locations~~and ~~set forth in~~ the ~~Agreements~~Hukui ~~(the~~Agreement ~~“Charging~~was ~~Stations”)~~terminated. ~~Under~~As ~~the~~a ~~Agreements~~result, we have ~~agreed~~no ~~to share~~continuing ~~our~~contractual ~~revenue~~obligation ~~generated~~to bymake ~~the~~any investment ~~sales of electricity at the Charging Stations with the Site Hosts~~ in ~~accordance with the schedules set forth therein~~Hukui.

As of December 31, 2022, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of December 31, 2022, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.14

AsResults of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities. The Company expects to install up to a total of 10 charging units for the first 2 sites, and have them operational in April of 2023.Operations

13Three-Month Period Ended March 31, 2023 compared to the Three-Month Period Ended March 31, 2022

~~Hukui Investment~~Revenues

~~Hukui Biotechnology~~We ~~Corporation~~did ~~(“Hukui”)~~not ~~and~~generate weany ~~entered into a Series C Preferred Shares Subscription Agreement dated September~~revenues ~~23,~~during ~~2020 (~~the ~~“Hukui~~three-month ~~Agreement”),~~period ~~pursuant~~ended ~~to which we agreed to purchase an aggregate 200~~March 31,~~000~~ ~~shares~~2023 ofand ~~Hukui’s Series C Preferred Stock (the “Series C Preferred Shares”) at $10~~2022.~~00 per share, for an aggregate investment of $2,000,000.~~

~~The Hukui~~Operating ~~Agreement provided that we would purchase the Series C Preferred Shares in three tranches, through a date on or before June 30, 2022, as follows:~~Expenses

●We ~~The~~incurred ~~first~~total ~~tranche~~operating isexpenses of 80$95,~~000~~839 ~~Series~~and C$62,085 ~~Preferred~~for ~~Shares~~the inthree-month ~~the~~periods ~~amount~~ended March 31, 2023 and 2022, respectively. Our operating expenses consist of legal ~~$800~~fees,~~000~~ ~~(the~~other ~~“First~~professional ~~Tranche~~fees, ~~Investment”)~~payroll expenses, ~~such~~stock-based ~~shares~~compensation, ~~having~~rent, ~~been~~bank ~~purchased~~charges, byand ustransfer onagent ~~December~~fees. 15The increase in operating expenses for the three-month period ended March 31, ~~2020~~2023 (compared to the ~~“First~~same ~~Tranche~~period ~~Closing”);~~ended in 2022 was primarily due to increase in payroll expenses and stock-based compensation.

●Other The second tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Second Tranche Investment”), such shares having been purchased by us on June 25, 2021 (the “Second Tranche Closing”); andexpense

●During ~~The~~the ~~third~~three-month period ~~tranche~~ended isMarch 31, 602023,~~000~~ ~~Series~~we Cincurred ~~Preferred~~$750 ~~Shares~~other inexpenses due to interest incurred for unpaid penalty from IRS. During the ~~amount~~three-month period ofended ~~$600~~March 31,~~000~~ ~~(the~~2022, ~~“Third~~we ~~Tranche~~incurred ~~Investment”)~~$1,145 ~~such~~other ~~shares~~expense was mainly due to ~~have~~interest ~~been~~incurred ~~purchased~~for onunpaid orpenalty ~~before~~from ~~June~~IRS. 30During the three months ended March 31, ~~2022~~2023, ~~(the~~we ~~“Third~~dissolved ~~Tranche~~our ~~Closing”)~~Singapore subsidiary, resulting a loss on disposal of subsidiary of $192,365.

~~An individual~~Net and resident of the Republic of China (the “Purchaser”), Hukui and we entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “Stock Purchase Agreement”), pursuant to which we agreed to sell the 140,000 shares of Hukui’s Series C Preferred Stock that we had purchased in the First Tranche Closing and the Second Tranche Closing (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.Loss

~~On December~~As ~~17,~~a ~~2021,~~result ~~Hukui~~of ~~and we entered into an Agreement (~~the ~~“Termination Agreement”)~~above, ~~pursuant to which~~ our ~~obligation to~~net ~~make~~loss ~~the~~increased ~~Third~~from ~~Tranche~~$63,224 ~~Investment~~in ~~was terminated and~~ the ~~Hukui~~three-month ~~Agreement~~period ~~was~~ended ~~terminated.~~March 31, As2022 ato ~~result~~$288,954 wein ~~have~~the nosame ~~continuing~~period ~~contractual obligation~~ended ~~to make any investment~~ in ~~Hukui~~2023.

14Six-Month Period Ended March 31, 2023 compared to the Six-Month Period Ended March 31, 2022

~~Results of Operations~~Revenues

~~Three~~We ~~Months Ended~~did ~~December~~not ~~31,~~generate ~~2022~~any ~~compared~~revenues during to the ~~Three~~six-month ~~Months~~periods ~~Ended~~ended ~~December~~ March 31, ~~2021~~2023 and 2022.

~~Revenues~~Operating Expenses

We ~~did~~ ~~not~~incurred ~~generate~~total ~~any~~operating ~~revenues~~expenses of ~~during~~$244,834 and $165,425 for the ~~three~~six-month ~~months~~periods ended ~~December~~March 31, 2023 and 2022, respectively. Our operating expenses consist of legal fees, other professional fees, payroll expenses, stock-based compensation, rent, bank charges, and transfer agent fees. The increase in operating expenses for the six-month period ended March 31, 2023 compared to the same period ended in 2022 was primarily due to increase in payroll expenses, and ~~2021~~stock-based compensation.

~~Operating~~Other ~~Expenses~~expense

WeDuring ~~incurred~~the ~~total~~six-month ~~operating~~period ~~expenses~~ended ofMarch 31, ~~$205~~2023,~~245~~ ~~and~~we incurred $~~103~~1,~~340~~500 ~~for~~other ~~the~~expenses ~~three~~mainly ~~months~~due ~~ended~~to ~~December~~interest ~~31,~~incurred ~~2022~~for ~~and~~unpaid ~~2021,~~penalty ~~respectively~~from IRS. ~~Our operating~~During ~~expenses~~the ~~consist~~six-month ofperiod ~~legal~~ended ~~fees~~March 31, ~~other professional fees~~2022, ~~payroll~~we ~~expenses,~~incurred ~~stock-based compensation~~$1,895 ~~rent,~~other ~~bank~~expenses ~~charges,~~mainly ~~and transfer~~due ~~agent~~to ~~fees.~~interest ~~The~~incurred ~~increase~~for inunpaid ~~operating~~penalty ~~expenses~~from IRS. ~~for~~During the ~~three~~six months ended ~~December~~March 31, ~~2022~~2023, ~~compared~~we todissolved ~~the~~our ~~same~~Singapore ~~period~~subsidiary, ~~in 2021~~resulting ~~was~~a ~~primarily~~loss ~~due~~on todisposal ~~the~~of ~~increase~~subsidiary ~~in payroll expenses~~of $192, ~~and stock-based compensation~~365.

~~Other~~Net ~~expense~~Loss

~~During the~~As ~~three~~a ~~months~~result ~~ended~~of ~~December~~the 31above, our ~~2022,~~net weloss ~~incurred~~increased ~~$793 other expenses mainly due to interest incurred for unpaid penalty~~ from ~~IRS. During~~$167,311 in the ~~three~~six-month ~~months~~period ended ~~December~~ March 31, ~~2021,~~2022 weto ~~incurred~~ $~~747~~438,742 ~~other~~in ~~expenses~~the ~~mainly~~same ~~due~~period toended ~~interest~~in ~~incurred for unpaid penalty from IRS~~2023.

~~Net~~Effect ~~Loss~~of the COVID-19 Pandemic on our Business

~~As a~~While ~~result~~our ofliquidity ~~the~~and capital ~~above,~~resources ~~our~~are ~~net~~severely ~~loss~~limited ~~increased~~and ~~from~~present ~~$104,087~~serious inobstacles ~~the~~to ~~three~~starting ~~months~~a ~~ended~~business, ~~December~~these ~~31,~~limitations ~~2021~~are unrelated to ~~$206,038~~the inCOVID-19 pandemic ~~the~~and ~~same~~resulting ~~period ended~~global ineconomic ~~2022~~crisis.

~~Effect~~Our ofpersonnel are in Taiwan, which has been relatively less affected by the pandemic compared to many other countries in Asia, Europe and the United States. However, even before an increase in the number of cases of COVID-19 ~~Pandemic~~in onTaiwan, ~~our~~we experienced delays in obtaining business licenses and ~~Business~~permits, and any other governmental approvals that might have been required for businesses that we previously considered commencing, since government offices have been working with reduced staff during the pandemic. We expect this situation to continue and possibly become more challenging depending upon the duration of the pandemic.

~~While our~~Depending ~~liquidity~~upon the extent and ~~capital~~duration ~~resources~~of ~~are~~the ~~severely~~pandemic ~~limited~~ and ~~present~~the ~~serious~~resulting ~~obstacles~~global toeconomic ~~starting a business~~crisis, these ~~limitations~~conditions ~~are~~may ~~unrelated to~~have ~~the~~an ~~COVID-19~~adverse ~~pandemic~~impact on our ability to raise capital and ~~resulting~~commence ~~global~~any ~~economic~~business ~~crisis~~we may pursue.

Our personnel are in Taiwan, which has been relatively less affected by the pandemic compared to many other countries in Asia, Europe and the United States. However, even before an increase in the number of cases of COVID-19 in Taiwan, we experienced delays in obtaining business licenses and permits, and any other governmental approvals that might have been required for businesses that we previously considered commencing, since government offices have been working with reduced staff during the pandemic. We expect this situation to continue and possibly become more challenging depending upon the duration of the pandemic.15

~~Depending upon~~Liquidity ~~the extent~~ and ~~duration of the pandemic and the resulting global economic crisis, these conditions may have an adverse impact on~~Capital ~~our ability to raise capital and commence any business we may pursue.~~Resources

~~Liquidity~~Working ~~and~~ Capital ~~Resources~~

Working Capital

	March 31,		September 30,
	2023		2022
Current Assets	$	320,670	$	150,893
Current Liabilities		104,931		205,016
Working Capital (Deficit)	$	215,739	$	(54,123	)

	December 31,			September 30,
	2022			2022
Current Assets	$	53,183		$	150,893
Current Liabilities		252,684			205,016
Working Capital Deficit	$	(199,501	)	$	(54,123	)

As of March 31, 2023, we had current assets of $320,670 and a working surplus of $215,739. In comparison, as of September 30, 2022, we had current assets of $150,893 and a working capital deficit of $54,123.

15As of March 31, 2023, we had total assets of $340,837, compared with total assets of $150,893 at September 30, 2022. The increase in total assets was primarily due to cash received from fundraising.

AsWe had $104,931 in total current liabilities as of ~~December~~March 31, ~~2022~~2023, weconsisting ~~had~~of ~~current~~$100,115 ~~assets~~in ofaccounts ~~$53~~payable,~~183~~ ~~and~~$40 ain ~~working~~accrued ~~deficit~~expenses ofand $~~199~~4,~~501~~776 due to related parties. InThis ~~comparison~~is compared to total current liabilities of $205,016 in total current liabilities as of September 30, 2022, weconsisting of ~~had~~$102,185 ~~current~~in ~~assets~~accounts ofpayable and $~~150~~102,~~893~~831 ~~and~~due ato ~~working~~related ~~capital~~parties. ~~deficit~~The ofdecrease ~~$54,123~~in due to related parties was primarily due to unpaid compensation to officers and directors repaid by shares.

~~As of~~We ~~December 31, 2022, we~~ had total ~~assets~~stockholders’ equity of $68205,~~188,~~180 ~~compared~~and ~~with~~an ~~total~~accumulated ~~assets~~deficit of $~~150~~10,~~893~~314,231 atas ~~September~~of 30March 31, ~~2022~~2023. ~~The~~In ~~decrease~~comparison, inwe had a total stockholders’ deficit ~~assets~~of ~~was~~$83,349 ~~primarily~~and ~~due~~an toaccumulated ~~cash~~deficit ~~spent~~of in$9,875,489 ~~operating~~as ~~expenses~~of September 30, 2022.

~~We had~~Cash $252,684 in total current liabilities as of December 31, 2022, consisting of $118,471 in accounts payable and $134,213 due to related parties. This is compared to total current liabilities of $205,016 as of September 30, 2022, consisting of $102,185 in accounts payable and $102,831 due to related parties. The increase in due to related parties was primarily due to unpaid compensation to officers and directors.Flows

We had total stockholders’ deficit of $214,472 and an accumulated deficit of $10,128,993 as of December 31, 2022. In comparison, we had a total stockholders’ deficit of $83,349 and an accumulated deficit of $9,922,955 as of September 30, 2022.

	Six Months Ended March 31, 2023			Six Months Ended March 31, 2022
Cash flows used in operating activities	$	(167,100	)	$	(116,306	)
Cash flows (used in) provided by investing activities		(20,167	)		350,000
Cash flows provided by financing activities		362,000			-
Net increase in cash during period	$	174,733		$	233,694

~~Cash~~During ~~Flows~~the six months ended March 31, 2023, we used $167,100 of cash in operating activities which was attributable primarily to our net loss of $438,742 offset by loss on disposal of subsidiary, stock-based compensation, and change in operating assets and liabilities of $271,642. In comparison, during the six months ended March 31, 2022, we used $116,306 of cash in operating activities which was attributable primarily to our net loss of $167,311 offset by change in operating assets and liabilities of $51,005.

	Three Months Ended December 31, 2022			Three Months Ended December 31, 2021
Cash flows used in operating activities	$	(74,869	)	$	(71,538	)
Cash flows used in investing activities		(15,005	)		350,000
Cash flows provided by financing activities		-			-
Effect of exchange rate changes on cash		-			-
Net increase (decrease) in cash during period	$	(89,874	)	$	278,462

During the six months ended March 31, 2023, we used $20,167 of cash investing activity in purchase of equipment. We received $350,000 in payment for the sale of the 140,000 Hukui Shares during the six months ended March 31, 2022.

During the ~~three~~six months ended ~~December~~March 31, ~~2022,~~2023 we ~~used~~received $74362,~~869~~000, ~~of cash in operating activities which was attributable primarily to our~~ net ~~loss~~ of ~~$206,038~~directly ~~offset~~associated bylegal ~~stock-based~~expenses ~~compensation~~from ~~and~~private ~~change~~offering inof ~~operating~~our ~~assets~~Common ~~and liabilities of $131,169~~Stock. ~~In comparison, during~~During the ~~three~~six months ended ~~December~~March 31, ~~2021~~2022, we ~~used~~did ~~$71,538~~not ofhave ~~cash~~any infinancing ~~operating activities which was attributable primarily to our net loss of $104,087 offset by change in operating assets and liabilities of $32,549~~activity.

~~During~~There is substantial doubt that we can continue as an ongoing business for the ~~three~~next twelve months ~~ended~~unless ~~December~~we ~~31,~~obtain ~~2022,~~additional capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until and unless we ~~used~~begin ~~$15,005~~to ofexecute ~~cash~~on inour ~~investing~~plan ~~activities~~of ~~for~~operations involving the ~~purchase~~start of ~~equipment~~our new electric vehicle charging station business. WeThere ~~received~~is ~~$350,000~~no assurance that we will ever reach that stage. The incondensed ~~payment~~consolidated ~~for~~financial statements presented herein do not include any adjustments relating to the ~~sale~~recoverability and classification of ~~the~~recorded ~~140~~assets,~~000~~ ~~Hukui~~or ~~Shares~~the ~~during~~amounts and classification of liabilities that might be necessary in the ~~three~~event ~~months~~that ~~ended~~we ~~December~~cannot ~~31,~~continue ~~2021~~as a going concern.

~~During the three months ended December 31, 2022 and 2021, we did not have any financing activity.~~16

~~There is~~Our ~~substantial~~ability ~~doubt~~to ~~that we can~~ continue as ana ~~ongoing~~going ~~business~~concern ~~for~~is ~~the~~dependent ~~next~~upon ~~twelve~~our ~~months~~ability ~~unless~~to wesuccessfully ~~obtain~~execute ~~additional capital to pay~~ our ~~expenses~~business asplan ~~they~~and ~~become~~generate ~~due.~~profitable Weoperations doin ~~not~~the ~~anticipate~~future, and, ~~any~~until ~~significant~~and ~~additional~~unless ~~revenue until~~ we ~~continue~~achieve that, to ~~implement~~obtain ~~our~~the ~~electric~~necessary ~~vehicle charging~~financing ~~station business operations and begin~~ to ~~profit~~meet ~~from~~ our ~~business~~obligations ~~operations.~~and ~~There~~repay isour noliabilities ~~assurance~~arising ~~that we will ever reach that~~from ~~stage.~~normal ~~The~~business ~~condensed~~operation ~~consolidated~~as ~~financial~~and ~~statements~~when ~~presented~~they ~~herein~~become dodue. ~~not~~To ~~include~~date, ~~any~~our ~~adjustments~~capital ~~relating~~requirements tohave ~~the~~primarily ~~recoverability and~~been ~~classification~~funded ofby ~~recorded~~shareholders ~~assets, or~~ through the ~~amounts~~purchase ~~and classification~~ of ~~liabilities~~our ~~that~~Common ~~might~~Stock ~~be necessary~~ in ~~the~~private ~~event~~offerings ~~that~~and weshort-term ~~cannot continue~~borrowings asfrom a ~~going~~former ~~concern~~officer and another shareholder.

~~Our ability~~The toCompany ~~continue as a going concern is dependent upon our ability to successfully execute our business plan and generate profitable~~sold the ~~operations~~140,000 Hukui inShares ~~the~~for ~~future~~$350,000 cash ~~and,~~on ~~until~~November ~~and unless we achieve that~~19, ~~to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operation as and when they become due~~2021. ToThe ~~date,~~proceeds ~~our capital requirements~~ have ~~primarily~~ been ~~funded~~ byused ~~shareholders~~for ~~through~~operation ~~the purchase of our Common Stock in private offerings and short-term borrowings from a former officer and another shareholder~~expenses.

~~The Company~~Contractual ~~sold the 140,000 Hukui Shares for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses.~~Obligations

16We do not have material contractual obligations and commitments. We only have one lease that is renewed on a month-to-month basis.

~~Contractual~~Off-Balance ~~Obligations~~Sheet Arrangements

WeAs of March 31, 2023, dowe had not ~~have~~entered ~~material~~into ~~contractual~~any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. As of March 31, 2023, we had not entered into any derivative contracts that are indexed to our shares and ~~commitments~~classified as shareholder’s equity or that are not reflected in our condensed consolidated financial statements. WeFurthermore, ~~only~~as ~~have~~of ~~one~~March ~~lease~~31, 2023, we had not had any retained or contingent interest in assets transferred to an unconsolidated entity that isserves ~~renewed~~as oncredit, aliquidity ~~month-~~or market risk support to~~-month~~ ~~basis~~such entity. As of March 31, 2023, we had not had any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

~~Off-Balance~~Critical ~~Sheet~~accounting ~~Arrangements~~policies and estimates

AsOur discussion and analysis of ~~December~~our ~~31,~~financial ~~2022,~~condition weand ~~had~~results ~~not~~of ~~entered~~operations ~~into~~are ~~any~~based ~~other~~upon our condensed consolidated financial ~~guarantees~~statements, orwhich have ~~other~~been ~~commitments~~prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to ~~guarantee~~make estimates and judgments that affect the ~~payment~~reported ~~obligations~~amounts of assets, liabilities, revenues and expenses, and related disclosure of ~~any~~contingent ~~third~~assets ~~parties~~and liabilities. AsWe ofcontinually ~~December~~evaluate 31our estimates, ~~2022,~~including wethose ~~had~~related ~~not~~to ~~entered~~income ~~into~~taxes, ~~any~~and ~~derivative~~the ~~contracts~~valuation ~~that~~of ~~are~~equity ~~indexed~~transactions. toWe base our ~~shares~~estimates ~~and~~on ~~classified~~historical asexperience ~~shareholder’s~~and ~~equity~~on orvarious ~~that~~other ~~are~~assumptions ~~not~~that ~~reflected~~we inbelieved ~~our~~to ~~condensed~~be ~~consolidated~~reasonable ~~financial~~under ~~statements.~~the ~~Furthermore~~circumstances, asthe results of ~~December~~which form the ~~31,~~basis ~~2022,~~for wemaking ~~had~~judgments ~~not~~about ~~had~~the ~~any~~carrying ~~retained~~values orof ~~contingent~~assets ~~interest~~and inliabilities ~~assets~~that ~~transferred~~are not readily apparent from other sources. Any future changes to anthese ~~unconsolidated~~estimates ~~entity~~and ~~that~~assumptions ~~serves~~could ascause ~~credit~~a material change to our reported amounts of revenues, expenses, ~~liquidity~~assets orand ~~market~~liabilities. ~~risk~~Actual ~~support~~results tomay ~~such~~differ ~~entity~~from these estimates under different assumptions or conditions. AsFor ofthe ~~December~~six months ended March 31, 2023 and 2022, weno ~~had~~significant ~~not~~estimates ~~had~~and ~~any~~assumptions ~~variable~~have ~~interest~~been made in ~~any~~the ~~unconsolidated~~condensed ~~entity~~consolidated financial ~~that~~statements. ~~provides~~The ~~financing,~~following ~~liquidity,~~are ~~market~~some ~~risk~~of orthe ~~credit~~critical ~~support~~accounting policies in relation to usthe orpreparation ~~engages~~of inthe ~~leasing~~condensed consolidated financial statements. For a full summary of our critical accounting policies, ~~hedging~~please orrefer ~~research~~to ~~and~~Note ~~development~~2 ~~services~~to the Condensed Consolidated ~~with~~Financial usStatements.

~~Critical~~Stock-Based ~~accounting policies and estimates~~Compensation

~~Our discussion~~We ~~and~~account ~~analysis~~for ~~of our financial condition and results of operations are~~ stock-based ~~upon our condensed consolidated financial statements,~~ ~~which~~compensation ~~have been prepared~~ in ~~accordance~~which ~~with~~we ~~accounting~~obtain ~~principles~~employee ~~generally~~services ~~accepted~~ in ~~the~~share-based ~~United~~payment ~~States.~~transactions ~~The~~under ~~preparation~~FASB ofASC ~~these~~Topic ~~condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets~~718, ~~liabilities, revenues~~Compensation ~~and~~– ~~expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those~~Stock ~~related to income taxes~~Compensation, ~~and~~which ~~the~~requires ~~valuation~~us ~~of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed~~ to beexpense ~~reasonable under~~ the ~~circumstances,~~cost ~~the results~~ of ~~which~~employee ~~form~~services ~~the~~received basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the three months ended December 31, 2022 and 2021, no significant estimates and assumptions have been made in ~~the~~exchange ~~condensed~~for ~~consolidated~~an ~~financial~~award ~~statements. The following are some~~ of ~~the~~equity ~~critical~~instruments ~~accounting~~based ~~policies~~on ~~in relation to~~ the ~~preparation~~grant ofdate ~~the~~fair ~~condensed~~value ~~consolidated financial statements. For a full summary~~ of ~~our~~such ~~critical~~instruments ~~accounting policies,~~over ~~please refer to Note 2 to~~ the ~~Condensed~~vesting ~~Consolidated Financial Statements~~period.

~~Foreign~~Recent ~~currency translation~~accounting pronouncements

~~The financial~~We ~~statements~~do ofnot ~~our~~expect ~~subsidiary denominated in currencies other than~~ that the ~~USD~~adoption ~~are~~of ~~translated~~recently ~~into~~issued ~~USD~~accounting ~~using~~pronouncements ~~the~~will ~~closing~~have ~~rate~~a ~~method. The~~material ~~balance~~impact ~~sheet~~on ~~items~~our ~~are~~financial ~~translated~~position, ~~into~~results ~~USD~~of ~~using~~operations, or ~~the~~cash ~~exchange rates at the respective balance sheet dates~~flows. For ~~The~~a ~~capital~~full ~~and~~summary ~~various reserves are translated at historical exchange rates prevailing at the time~~ of ~~the~~recent ~~transactions~~accounting ~~while~~pronouncements, ~~income~~please ~~and~~refer ~~expenses~~to ~~items~~Note ~~are~~2 ~~translated at~~to the ~~average~~Condensed ~~exchange~~Consolidated ~~rate for the period~~Financial Statements. ~~All exchange differences are recorded in stockholders’ equity.~~

~~Stock-Based~~Currency ~~Compensation~~exchange rates

WeFor financial reporting purposes, ~~account~~the ~~for~~financial ~~stock-based~~statements ~~compensation~~of inthe Company’s Singapore subsidiary, which weare ~~obtain~~prepared ~~employee~~using ~~services~~the inSGD, ~~share-based~~are ~~payment~~translated ~~transactions~~into ~~under~~the ~~FASB~~Company’s reporting ~~ASC~~currency, ~~Topic~~USD. Assets ~~718~~and liabilities are translated using the exchange rate on the balance sheet date, which was 0.6970 ~~Compensation~~as –of ~~Stock~~September ~~Compensation~~30, ~~which~~2022, ~~requires~~respectively. usRevenue toand ~~expense~~expenses ~~the~~are ~~cost~~translated ofusing ~~employee~~average ~~services~~exchange ~~received~~rates inprevailing during each reporting period. The 0.7383 average exchange rates were used to translate revenues and expenses for anthe ~~award~~six months ended March of31, 2022. Stockholders’ equity ~~instruments~~is ~~based~~translated onat historical exchange rates. Adjustments resulting from the ~~grant~~translation ~~date~~are ~~fair~~recorded as ~~value~~a separate component of ~~such~~accumulated ~~instruments~~other ~~over~~comprehensive ~~the~~loss ~~vesting~~in ~~period~~stockholders’ deficit.

~~Recent accounting pronouncements~~17

~~We do~~ITEM ~~not expect that the adoption of recently issued accounting pronouncements will have a material impact on our financial position, results of operations, or cash flows~~3. ~~For~~ aQUANTITATIVE ~~full~~AND ~~summary~~QUALITATIVE ofDISCLOSURE ~~recent~~ABOUT ~~accounting~~MARKET ~~pronouncements, please refer to Note 2 to the Condensed Consolidated Financial Statements~~RISK.

~~Currency~~Not ~~exchange~~required ~~rates~~for smaller reporting companies.

~~For financial~~ITEM ~~reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD~~4. ~~Assets~~ ~~and~~CONTROLS ~~liabilities~~AND ~~are translated using the exchange rate on the balance sheet date, which was 0~~PROCEDURES.7464 and 0.6970 as of December 31, and September 30, 2022, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7214 and 0.7370 average exchange rates were used to translate revenues and expenses for the three months ended December 31, 2022 and 2021, respectively. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ deficit.

17Evaluation of Disclosure Controls and Procedures

~~ITEM~~Our disclosure controls and procedures are designed to ensure that the information relating to our Company, including our consolidated subsidiary, required to be disclosed in our reports filed with the Securities and Exchange Commission (the “SEC”) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 313a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report. Based ~~QUANTITATIVE~~on ~~AND~~this ~~QUALITATIVE~~evaluation, ~~DISCLOSURE~~our ~~ABOUT~~chief ~~MARKET~~executive ~~RISK~~officer and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as described below.

~~Not required~~Management’s ~~for~~Report ~~smaller~~on ~~reporting~~Internal ~~companies.~~Control Over Financial Reporting

~~ITEM~~Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 413a-15(f) and 15d-15(f). Under the supervision and with the participation of management, including our chief executive officer and chief financial ~~CONTROLS~~officer, ~~AND~~we ~~PROCEDURES~~conducted an evaluation of the design and operating effectiveness of our internal controls over financial reporting based on the framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

~~Evaluation~~Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of ~~Disclosure~~records ~~Controls~~that, in reasonable detail, accurately and ~~Procedures~~fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

~~Our disclosure~~Management ~~controls~~assessed ~~and procedures are designed to ensure that~~ the information relating to our Company, including our consolidated subsidiary, required to be disclosed in our reports filed with the Securities and Exchange Commission (the “SEC”) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness ~~of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e)~~ ~~and 15d-15(e) under the Securities Exchange Act~~ of ~~1934, as amended) as of~~ the ~~end~~Company’s ofinternal ~~the~~control ~~period~~over ~~covered by this annual report. Based on this evaluation, our chief executive officer and chief~~ financial ~~officer~~reporting ~~concluded that,~~ as of ~~the~~March ~~evaluation date~~31, ~~our~~2023 ~~disclosure controls~~ and ~~procedures~~identified ~~were~~the ~~not~~following ~~effective due to~~ material weaknesses ~~in our internal control over financial reporting, as described below.~~:

~~Management’s~~Inadequate Segregation ~~Report~~of onDuties: ~~Internal~~We ~~Control~~have ~~Over~~an ~~Financial~~inadequate ~~Reporting~~number of personnel to properly implement control procedures.

~~Our management~~Comingling isof ~~responsible~~funds: ~~for~~We do ~~establishing~~not ~~and~~have ~~maintaining~~ adequate ~~internal~~ control ~~over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation~~ of ~~management, including~~ our ~~chief executive~~petty ~~officer and chief financial officer~~cash, weresulting ~~conducted~~in ~~an evaluation of~~ the ~~design~~comingling ~~and operating effectiveness~~ of our ~~internal~~petty ~~controls over~~cash ~~financial~~with ~~reporting based on~~ the ~~framework~~nominal inaccount ~~“Internal Control-Integrated Framework (2013)” issued by the Committee~~holder’s ofpersonal ~~Sponsoring Organizations of the Treadway Commission (“COSO”)~~funds.

~~Our internal~~Lack ~~control over financial reporting includes those policies and procedures that (i) pertain to the maintenance~~ of ~~records~~Adequate ~~that,~~Staffing: inWe ~~reasonable~~do ~~detail,~~not ~~accurately~~have ~~and~~adequate ~~fairly~~in-house ~~reflect~~accounting ~~the~~personnel ~~transactions~~ and ~~dispositions~~expertise ofin ~~the~~key ~~assets;~~positions, ~~(ii)~~which ~~provide~~resulted ~~reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements~~ in ~~accordance~~overly ~~with~~relying ~~generally~~on ~~accepted~~outside ~~accounting~~consultants ~~principles, and that receipts and expenditures are being made only~~ in ~~accordance~~preparing ~~with~~financial ~~authorizations~~statements ~~of management~~ and ~~directors; and~~other ~~(iii)~~required ~~provide~~disclosures ~~reasonable~~by ~~assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on~~ the ~~consolidated~~Securities ~~financial~~and ~~statements~~Exchange Commission.

~~Management~~Ineffective oversight: ~~assessed~~We ~~the~~do ~~effectiveness~~not ofexercise ~~the~~effective ~~Company’s~~oversight ~~internal~~and ~~control~~monitoring ~~over~~procedures ~~financial~~designed ~~reporting as of December 31, 2022~~ and ~~identified~~implemented ~~the following~~to ~~material~~certain ~~weaknesses:~~control activities.

~~Inadequate Segregation~~Overly ofrelied ~~Duties~~on outside professionals: We ~~have~~are anunable ~~inadequate~~to ~~number~~prepare ofinternally ~~personnel~~financial statements and relied on outside professional consultants to ~~properly~~prepare financial ~~implement~~statements ~~control~~and ~~procedures~~adequate disclosures.

~~Comingling of funds: We do not have adequate control of our petty cash, resulting in the comingling of our petty cash with the nominal account holder’s personal funds.~~18

~~Lack~~A material weakness is a deficiency, or a combination of ~~Adequate~~deficiencies, ~~Staffing:~~in Weinternal docontrol over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not ~~have~~be ~~adequate~~prevented ~~in-house~~or ~~accounting~~detected ~~personnel~~on ~~and~~a ~~expertise~~timely basis. As a result of the material weaknesses in ~~key~~internal ~~positions~~control over financial reporting identified above, ~~which~~management ~~resulted~~concluded inthat ~~overly~~the Company’s ~~relying~~internal oncontrol ~~outside~~over ~~consultants~~financial inreporting ~~preparing~~was ~~financial~~not ~~statements~~effective ~~and~~as ~~other~~of ~~required~~March ~~disclosures~~31, by2023 based on the ~~Securities~~criteria ~~and~~set ~~Exchange~~forth ~~Commission~~in “Internal Control-Integrated Framework” issued by COSO.

~~Ineffective~~Due to the nature of the material ~~oversight:~~weaknesses, Wethere dois a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not ~~exercise~~be ~~effective~~prevented ~~oversight~~or ~~and~~detected. ~~monitoring~~The ~~procedures~~material ~~designed~~weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s condensed consolidated financial statements at and ~~implemented~~for tothe three-month ~~certain~~periods ~~control~~ended ~~activities~~March 31, 2023.

~~Overly relied~~Management’s onPlan ~~outside~~for ~~professionals: We are unable to prepare internally financial statements and relied on outside professional consultants to prepare financial statements and adequate disclosures.~~Remediation

18Management has discussed the material weaknesses noted above with our independent registered public accounting firm. Management is committed to improving its internal controls and, subject to having adequate financial resources, intends to:

~~A material~~● ~~weakness~~increase isthe afrequency ~~deficiency, or a combination~~ of ~~deficiencies,~~independent inreconciliations ~~internal control over financial reporting, such that there is a reasonable possibility that a material misstatement~~ of ~~the~~significant ~~Company’s~~accounts ~~annual~~which ~~or interim financial statements~~ will ~~not~~mitigate bethe ~~prevented or~~lack ~~detected on a timely basis. As a result~~ of ~~the~~segregation ~~material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial reporting was not effective as~~ of ~~December~~duties ~~31,~~to ~~2022 based on~~monitor ~~the~~and ~~criteria~~review ~~set~~until ~~forth~~there inare ~~“Internal~~sufficient ~~Control-Integrated~~personnel ~~Framework”~~to ~~issued~~segregate ~~by COSO.~~duties;

~~Due to~~● ~~the~~consider ~~nature~~providing ofprofessional ~~the~~courses material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s condensed consolidated financial statements at and for ~~the~~our ~~three-month~~key ~~periods~~position ~~ended December 31, 2022.~~personnel;

~~Management’s Plan~~● ~~for~~hire ~~Remediation~~additional employees to realize segregation of duties; and

~~Management has~~● ~~discussed~~strengthen ~~the~~management ~~material~~monitoring ~~weaknesses~~control ~~noted~~over ~~above with our independent registered public~~ accounting ~~firm. Management is committed to improving its internal controls~~ and, ~~subject to having adequate~~ financial ~~resources,~~statements ~~intends~~preparation ~~to:~~processing.

●However, ~~increase~~due ~~the~~to ~~frequency~~ limitation of ~~independent~~funds ~~reconciliations~~and ofpersonnel, ~~significant~~we ~~accounts~~have ~~which~~so ~~will~~far ~~mitigate~~been ~~the~~unable ~~lack~~to ofbegin ~~segregation~~to ofimplement ~~duties~~the plan to ~~monitor~~remediate the material weaknesses noted above and it ~~review~~is ~~until~~uncertain ~~there~~when ~~are~~we ~~sufficient~~will ~~personnel~~be able to ~~segregate~~begin ~~duties;~~to implement the plan to remediate these material weaknesses.

●Inherent ~~consider~~Limitations ~~providing~~on ~~professional~~Effectiveness ~~courses~~of ~~for our key position personnel;~~Controls

●A ~~hire~~control ~~additional~~system, ~~employees~~no tomatter how ~~realize~~well ~~segregation~~designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of ~~duties;~~its inherent limitations, internal control over financial reporting may not prevent or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become adequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

●Changes ~~strengthen~~in ~~management~~Internal ~~monitoring control over accounting and financial statements preparation processing.~~Control

~~However, due~~There ~~to limitation of funds and personnel, we~~ have sobeen ~~far~~no ~~been~~changes in ~~unable~~our tointernal ~~begin~~control toover ~~implement~~financial ~~the~~reporting ~~plan~~that tooccurred ~~remediate~~during the ~~material~~period ~~weaknesses noted~~covered ~~above~~by ~~and~~this itreport isthat ~~uncertain~~have ~~when~~materially weaffected, or ~~will~~are bereasonably ~~able~~likely to ~~begin~~materially toaffect, ~~implement~~our ~~the~~internal ~~plan~~control toover ~~remediate~~financial ~~these material weaknesses~~reporting.

~~Inherent Limitations on Effectiveness of Controls~~19

~~A control~~PART system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become adequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.II

~~Changes in~~OTHER ~~Internal Control~~INFORMATION

~~There have~~ITEM ~~been~~1. noLEGAL changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.PROCEEDINGS

19We are not currently a party to any lawsuit or proceeding, which, in the opinion of management, is likely to have a material adverse effect on us or our business.

~~PART II~~ITEM 1A. RISK FACTORS

~~OTHER~~Not required of smaller reporting ~~INFORMATION~~companies.

ITEM 1 2. ~~LEGAL~~ ~~PROCEEDINGS~~UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

WeOn ~~are~~February ~~not~~24, ~~currently~~2023 (the “Closing Date”), GenuFood Energy Enzymes Corp. (the “Company”) entered into a ~~party~~Subscription Agreement with each of certain subscribers (each, a “Purchaser” and collectively, the “Purchasers”) who have subscribed to ~~any~~purchase ~~lawsuit~~a orcertain ~~proceeding~~amount of shares of common stock of the Company, ~~which~~par value 0.001 (the “Common Stock”), as set forth in that respective purchasers Subscription Agreement, each subscribing for not less than $5,000 and up to 5,000,000 shares at a purchase price of US$0.001 per share. The Company was conducting this private offering (the ~~opinion~~“Offering”) pursuant to a private placement memorandum (the “PPM”) whereby the Company was offering and selling a minimum amount of ~~management~~$500,000 is(the ~~likely~~“Minimum Offering Amount”) and maximum of $1,000,000 of its common shares to ~~have~~accredited ainvestors ~~material~~and ~~adverse~~non-U.S. ~~effect~~persons. onThe usgross orproceeds ~~our~~from ~~business~~the private placement were $375,000.00.

~~ITEM 1A.~~The shares of Common Stock ~~RISK~~issued ~~FACTORS~~and sold under the Subscription Agreement as described above were offered and sold by the Company in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D thereunder.

~~Not required~~ITEM of3. ~~smaller~~DEFAULTS ~~reporting~~UPON ~~companies.~~SENIOR SECURITIES

~~ITEM 2~~None. ~~UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~

~~None~~ITEM 4. MINE SAFETY DISCLOSURES

~~ITEM 3. DEFAULTS~~Not ~~UPON SENIOR SECURITIES~~applicable.

~~None~~ITEM 5. OTHER INFORMATION

~~ITEM 4~~None. ~~MINE SAFETY DISCLOSURES~~

~~Not applicable.~~20

ITEM 5 6. ~~OTHER~~ ~~INFORMATION~~EXHIBITS

None.

Exhibit No.		Description
31.1		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
31.2		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
32.1*		Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

20* The certifications attached as Exhibits 32.1 and 32.2 accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

~~ITEM 6. EXHIBITS~~21

Exhibit No.		Description
31.1		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
31.2		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
32.1*		Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

*Pursuant ~~The certifications attached as Exhibits 32.1 and 32.2 accompany this quarterly report on Form 10-Q pursuant~~ to 18the ~~U.S.C.~~requirements ~~Section~~of ~~1350, as adopted pursuant to~~ Section 13 or ~~906~~15(d) of the ~~Sarbanes-Oxley~~Securities Exchange Act of ~~2002~~1934, ~~and~~the ~~shall~~registrant ~~not~~has beduly ~~deemed~~caused ~~“filed”~~this byreport ~~the~~to ~~Registrant~~be ~~for~~signed ~~purposes~~on ofits ~~Section~~behalf 18by of the ~~Securities Exchange Act of 1934~~undersigned, thereunto asduly ~~amended~~authorized.

	GENUFOOD ENERGY ENZYMES CORP.

Date: June 2, 2023	By:	/s/ David Tang
		David Tang
		Chief Executive Officer

	By:	/s/ Shao-Cheng Wang
		Shao-Cheng Wang
		Chief Financial Officer

~~SIGNATURES~~22

~~Pursuant~~ ~~to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to~~ be--09-30 Genufood ~~signed~~Energy onEnzymes ~~its behalf by the undersigned, thereunto duly authorized~~Corp. NONE Yes 68-0681158 Yes 299686921 299686921 385390227 473950309 false Q2 false 0001510518 0001510518 2022-10-01 2023-03-31 0001510518 2023-03-31 0001510518 2022-09-30 0001510518 2023-01-01 2023-03-31 0001510518 2022-01-01 2022-03-31 0001510518 2021-10-01 2022-03-31 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001510518 2022-10-01 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001510518 us-gaap:CommonStockMember 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001510518 2022-12-31 0001510518 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001510518 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001510518 us-gaap:CommonStockMember 2023-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2023-03-31 0001510518 us-gaap:RetainedEarningsMember 2023-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001510518 2021-10-01 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001510518 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001510518 us-gaap:CommonStockMember 2022-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001510518 2022-03-31 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2022-09-01 2022-09-30 0001510518 gfoo:HukuiBiotechnologyCorporationMember 2021-11-19 0001510518 2021-11-01 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-19 2021-11-19 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 us-gaap:StockOptionMember 2022-10-01 2023-03-31 0001510518 us-gaap:StockOptionMember 2022-09-01 2022-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2023-03-31 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2023-03-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2023-03-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2023-03-31 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2023-03-31 0001510518 gfoo:NanYaoJakeChanMember 2022-10-01 2023-03-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2023-03-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2023-03-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2023-03-31 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2023-03-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2023-03-31 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2023-03-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2023-03-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2023-03-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:DavidTangMember 2023-03-31 0001510518 gfoo:DavidTangMember 2022-09-30 0001510518 2019-10-01 2020-09-30 0001510518 2023-03-29 2023-03-31 0001510518 2020-10-01 2021-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

	GENUFOOD ENERGY ENZYMES CORP.
Date: February 14, 2023	By:	/s/ David Tang
		David Tang
		Chief Executive Officer
	By:	/s/ Shao-Cheng Wang
		Shao-Cheng Wang
		Chief Financial Officer

NONE Yes 68-0681158 Yes 299686921 299686921 false --09-30 Q1 2023 false 0001510518 0001510518 2022-10-01 2022-12-31 0001510518 2023-02-13 0001510518 2022-12-31 0001510518 2022-09-30 0001510518 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-10-01 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001510518 us-gaap:CommonStockMember 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-10-01 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001510518 2021-12-31 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationMember 2021-11-19 0001510518 2021-11-10 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-01 2021-11-19 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 2021-10-01 2022-09-30 0001510518 us-gaap:StockOptionMember 2021-10-01 2022-09-30 0001510518 us-gaap:StockOptionMember 2022-10-01 2022-12-31 0001510518 2020-10-01 2021-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2022-12-31 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2022-12-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2022-12-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2022-12-31 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2022-12-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2022-12-31 0001510518 gfoo:NanYaoJakeChanMember 2022-10-01 2022-12-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2022-12-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2022-12-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-12-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-12-31 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-12-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-12-31 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-12-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-12-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-12-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:NaoYaoJakeChanMember 2022-12-31 0001510518 gfoo:NaoYaoJakeChanMember 2022-09-30 0001510518 2019-10-01 2020-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Filing Compare · Genufood Energy Enzymes Corp.